Eiger BioPharmaceuticals 2018-03-13T10:47:27+00:00

IN THE NEWS

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™

June 4th, 2018|

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ PALO ALTO, Calif., June 4, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation from the Phase 2 LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program as well as an update on the Phase 3 D-LIVR study [...]

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

May 30th, 2018|

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PALO ALTO, Calif. – May 30, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory, President and CEO, will present a corporate update at Jefferies 2018 Global Healthcare Conference on June 5th at 4:00 PM ET.  The corporate update will include a discussion of recent progress across all Eiger programs including Hepatitis Delta Virus [...]

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

May 24th, 2018|

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PALO ALTO, Calif., May 24, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced that it is selling 3,200,000 shares of its common stock in the public offering at an offering price of $12.50 per share.  In connection with the [...]